|Articles|May 11, 2009

Responding to a Critique of the Industry

Critical comments of the drug evaluation process bring about strong reaction from industry.

In a recent analytical article and additional commentary published in BMJ, the drug evaluation process suffered heavy criticism. The controversial articles-which can be found below-elicited strong reactions from industry leaders including, Dr. Beat Widler, Professor Gerfried Nell, Dr. Uwe Gudat, and Thorsten Ruppert. Continue reading to hear clinical trials professionals defend and discuss the depictions made in the BMJ publications.

“Patients and the public deserve big changes in evaluation of drugs,” Silvio Garattini, director, Mario Negri Institute for Pharmacological Research, Via Giuseppe La Masa 19, 20156 Milan, Italy; and Iain Chalmers, editor, James Lind Library, 2 Summertown Pavilion, Oxford OX2 7LG, U.K.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Responding to a Critique of the Industry

Related Content

Inside the FDA's Commissioner's National Priority Voucher Program: Promise, Pressure, and Operational Reality

End of FDA Commissioner Makary’s Tumultuous Tenure Leaves Agency in Transition

FDA Clears Investigational New Drug Application for Phase Ib/IIa Trial of CK0802 in Steroid-Refractory Graft-Versus-Host Disease

FDA Launches Proof-of-Concept Real-Time Clinical Trials

Why Trial Design Has Become a Leadership Decision

Trending on Applied Clinical Trials Online

The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck

A Shot in the Arm to Traditional Vaccine Trial Strategy

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention

SCOPE X: What Real-Time Patient Data Is Doing to ClinOps Efficiency

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years